Adam Savitz
Known title: CHIEF MEDICAL OFFICERCIK: 0002008707
Adam Savitz's purchase track record
Adam Savitz has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/9/2024 | ANRO | $191K | -14.4% | -65.6% | +5.9% |
| 2/6/2024 | ANRO | $272K | -22.6% | -49.6% | +5.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANRO | ▲ Buy | Open Market | 2,931 | $39K | 7/10/2024 | View on chart |
| ANRO | ▲ Buy | Open Market | 10,681 | $134K | 7/9/2024 | View on chart |
| ANRO | ▲ Buy | Open Market | 1,388 | $18K | 7/9/2024 | View on chart |
| ANRO | ▼ Sell | Other | 7,851 | — | 2/6/2024 | View on chart |
| ANRO | ▲ Buy | Open Market | 17,000 | $272K | 2/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ANRO mentioned in review of lagging medical stocks
A Yahoo article reviewing medical sector performance noted that many medical stocks have lagged behind Cardinal Health this year. Alto Neuroscience, as a medical‑focused company, is part of that broader discussion. The stock is currently near the lower end of its 52‑week range, which aligns with the sector’s weaker momentum.
ANRO mentioned in review of lagging medical stocks. A Yahoo article reviewing medical sector performance noted that many medical stocks have lagged behind Cardinal Health this year. Alto Neuroscience, as a medical‑focused company, is part of that broader discussion. The stock is currently near the lower end of its 52‑week range, which aligns with the sector’s weaker momentum.